John G Gerber

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Lack of an effect of age on beta-adrenoceptor-mediated lipolysis in isolated human adipocytes
    J G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, USA
    J Gerontol A Biol Sci Med Sci 54:B71-7. 1999
  2. ncbi request reprint Therapeutic drug monitoring in the treatment of HIV-infection
    John G Gerber
    Divisions of Clinical Pharmacology and Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Virol 27:117-28. 2003
  3. ncbi request reprint Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study
    John G Gerber
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 39:307-12. 2005
  4. ncbi request reprint Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401
    J G Gerber
    University of Colorado Health Sciences Center, 4200 E 9th Avenue, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 27:153-60. 2001
  5. ncbi request reprint Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Chirality 16:36-44. 2004
  6. ncbi request reprint Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction
    David L Wyles
    Department of Medicine, Divisions of Infectious Diseases and Clinical Pharmacology, University of Colorado Health Sciences Center, Denver, USA
    Clin Infect Dis 40:174-81. 2005
  7. doi request reprint Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers
    Jennifer J Kiser
    Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:570-8. 2008
  8. pmc Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:459-66. 2008
  9. ncbi request reprint Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs
    Jennifer J Kiser
    Division of Clinical Pharmacology, University of Colorado Health Science Center, Denver, CO 80262, USA
    Curr HIV/AIDS Rep 2:61-7. 2005
  10. ncbi request reprint Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates
    Shahrzad Dilmaghanian
    Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Chirality 16:79-85. 2004

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Lack of an effect of age on beta-adrenoceptor-mediated lipolysis in isolated human adipocytes
    J G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, USA
    J Gerontol A Biol Sci Med Sci 54:B71-7. 1999
    ..These data suggest that neither beta 1- nor beta 2-adrenoceptor responses in human adipocytes show significant changes due to aging...
  2. ncbi request reprint Therapeutic drug monitoring in the treatment of HIV-infection
    John G Gerber
    Divisions of Clinical Pharmacology and Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Virol 27:117-28. 2003
    ..At this point in time we consider TDM in the treatment of HIV-infection as experimental with significant promise for the future...
  3. ncbi request reprint Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study
    John G Gerber
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 39:307-12. 2005
    ..The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA...
  4. ncbi request reprint Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401
    J G Gerber
    University of Colorado Health Sciences Center, 4200 E 9th Avenue, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 27:153-60. 2001
    ..The effect of ritonavir 400 mg/saquinavir 400 mg twice daily on the stereoselective pharmacokinetics of methadone was examined in 12 HIV-infected, methadone-using study subjects...
  5. ncbi request reprint Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Chirality 16:36-44. 2004
    ....
  6. ncbi request reprint Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction
    David L Wyles
    Department of Medicine, Divisions of Infectious Diseases and Clinical Pharmacology, University of Colorado Health Sciences Center, Denver, USA
    Clin Infect Dis 40:174-81. 2005
    ....
  7. doi request reprint Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers
    Jennifer J Kiser
    Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:570-8. 2008
    ..Tolerability and lipid changes were also assessed...
  8. pmc Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:459-66. 2008
    ..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
  9. ncbi request reprint Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs
    Jennifer J Kiser
    Division of Clinical Pharmacology, University of Colorado Health Science Center, Denver, CO 80262, USA
    Curr HIV/AIDS Rep 2:61-7. 2005
    ..Nevertheless, there are specific clinical instances where this experimental intervention should be considered to potentially reduce toxicity and improve therapeutic outcomes...
  10. ncbi request reprint Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates
    Shahrzad Dilmaghanian
    Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Chirality 16:79-85. 2004
    ..Overall, levo-KTZ was 2-4-fold more active than dextro-KTZ. Therefore, levo-KTZ is a more potent inhibitor of CYP3A4 and has stronger in vitro antifungal activity. Chirality 16:79-85, 2004...
  11. pmc Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir
    David W Haas
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 50:290-3. 2009
    ..Rifampin is the cornerstone of antituberculosis therapy, but induction of hepatic cytochrome P4503A by rifampin markedly lowers HIV protease inhibitor plasma concentrations...
  12. ncbi request reprint Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
    Carl J Fichtenbaum
    University of Cincinnati College of Medicine, Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, Ohio 45267 0405, USA
    AIDS 16:569-77. 2002
    ....
  13. ncbi request reprint Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection
    Carl J Fichtenbaum
    Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Clin Pharmacokinet 41:1195-211. 2002
    ....
  14. pmc Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 51:3104-10. 2007
    ..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
  15. ncbi request reprint Position paper on therapeutic drug monitoring of antiretroviral agents
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 18:825-34. 2002
    ..This position paper offers guidelines to aid clinicians who choose to incorporate TDM into the routine care of their patients...
  16. pmc Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108
    Judith A Aberg
    New York University, New York, New York, USA
    AIDS 20:725-9. 2006
    ..Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia...
  17. ncbi request reprint Protein binding in antiretroviral therapies
    Marta Boffito
    St Stephens Centre, Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom
    AIDS Res Hum Retroviruses 19:825-35. 2003
    ....
  18. ncbi request reprint Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    J Pharmacokinet Pharmacodyn 33:399-419. 2006
    ..But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates...
  19. ncbi request reprint Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)
    Barbara M Gripshover
    University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
    Antivir Ther 11:619-23. 2006
    ..Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses...
  20. ncbi request reprint The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
    Arlene S Pereira
    Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 186:198-204. 2002
    ..The antiretroviral effect of APV monotherapy was related to APV concentrations...
  21. ncbi request reprint Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 78:143-53. 2005
    ..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
  22. ncbi request reprint The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing
    David J Back
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    J Acquir Immune Defic Syndr 39:S1-23, quiz S24-25. 2005
    ....
  23. ncbi request reprint Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Acquir Immune Defic Syndr 39:272-83. 2005
    ..The proposed mathematic models and statistical techniques may provide a framework to simulate and predict antiviral response for individual patients...
  24. ncbi request reprint Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy
    Jennifer R King
    University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama, USA
    AIDS 19:1059-63. 2005
    ..To describe the in vivo protein-binding characteristics of indinavir (IDV) in the presence of ritonavir (RTV) relative to total IDV plasma concentrations...
  25. ncbi request reprint Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism
    David Dunmire
    Department of Chemistry, Syracuse University, Syracuse, New York 13244 4100, USA
    Chirality 17:S101-8. 2005
    ....
  26. ncbi request reprint Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
    Morris Schambelan
    University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
    J Acquir Immune Defic Syndr 31:257-75. 2002
    ..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
  27. ncbi request reprint Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity
    Marshall J Glesby
    AIDS Read 13:346-7. 2003
  28. ncbi request reprint Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    J Acquir Immune Defic Syndr 37:1358-66. 2004
    ....
  29. ncbi request reprint Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult
    Michael P Dube
    Indiana University, Indianapolis, USA
    Clin Infect Dis 37:613-27. 2003
  30. ncbi request reprint Abacavir pharmacokinetics in hepatic dysfunction
    David L Wyles
    Clin Infect Dis 40:909-10. 2005